Quarterly report pursuant to Section 13 or 15(d)

Licenses Acquired - Narrative (Details)

v3.23.1
Licenses Acquired - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Apr. 27, 2023
Feb. 28, 2023
Oct. 11, 2022
Mar. 31, 2023
Mar. 31, 2022
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Expenses recognized       $ 39,506 $ 36,722
Avenue          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Common shares issued (in shares)     3,636,365    
Avenue | AnnJi Pharmaceutical Co          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Upfront fees payment   $ 3,000      
Amount reimbursable $ 1,000        
Payments of milestones $ 2,000        
Common shares issued (in shares)   831,618      
Expenses recognized   $ 900      
Avenue | AnnJi Pharmaceutical Co | Additional Indication Milestones          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Additional fees due   27,500      
Expenses recognized   300      
Avenue | AnnJi Pharmaceutical Co | Additional Sales Milestone Payments          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Additional fees due   165,000      
Avenue | Minimum | AnnJi Pharmaceutical Co | Additional Sales Milestone Payments          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Additional fees due   75,000      
Avenue | Minimum | License agreements | AnnJi Pharmaceutical Co | Additional Sales Milestone Payments          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Additional fees due   50,000      
Avenue | Maximum | AnnJi Pharmaceutical Co | First Indication Milestones          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Payments of milestones   10,800      
Avenue | Maximum | AnnJi Pharmaceutical Co | Additional Sales Milestone Payments          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Additional fees due   750,000      
Avenue | Maximum | DFD Agreement [Member] | AnnJi Pharmaceutical Co | First Indication Milestones          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Additional fees due   14,500      
Avenue | Maximum | License agreements | AnnJi Pharmaceutical Co | Additional Sales Milestone Payments          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Additional fees due   $ 300,000